Graft Failure clinical trials

Explore recruiting graft failure clinical trials.

Recruiting graft failure studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Graft Failure trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II study on Venetoclax (VEN) plus Decitabine (DEC) (VEN-DEC) for elderly (≥60 <75years) patients with newly diagnosed Acute Myeloid Leukemia (AML) elegible for allogeneic Stem Cell Transplantation (allo-SCT)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts

Germany, Sweden, Belgium, Czechia, Austria, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, post-authorisation long-term follow up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort

Spain, Czechia, Belgium, Sweden, France, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN)

Germany, Austria, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, randomized, non-comparative multi-center phase I/II study to assess the safety and the efficacy of SMART101 after HLA-mismatched peripheral blood stem cell transplantation with post-transplant cyclophosphamide in patients with hematological malignancies

Italy, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppression versus stopping immunosuppression at 6 months to safely prevent human leukocyte antigen (HLA) sensitization in patients with late renal graft failure

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Graft Failure trials by city

Graft Failure in Toronto Graft Failure in Vancouver Graft Failure in Montreal Graft Failure in Calgary Graft Failure in Edmonton Graft Failure in Ottawa Graft Failure in Winnipeg Graft Failure in Quebec City Graft Failure in Hamilton Graft Failure in Kitchener Graft Failure in London Graft Failure in Halifax Graft Failure in New York Graft Failure in Los Angeles Graft Failure in Chicago Graft Failure in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease